Education

PhD Tumor Immunology.
University of Groningen, Groningen, The Netherlands. 

Nov 2011- Mar 2016

​

MSc Human Pathobiology & Toxicology.
Radboud University Nijmegen, Nijmegen, The Netherlands.

Sep 2009 - Aug 2011

​

BSc Biomedical Sciences.
Radboud University Nijmegen, Nijmegen, The Netherlands.

Sep 2005 - Aug 2009

​

​

​

Work Experience

Freelance Medical and Science Writer and Editor

Wouters Writing, Victoria, BC, Canada

January 2020 - Present

​

Postdoctoral Research Fellow Cancer Immunotherapy

BC Cancer, Victoria, BC, Canada

March 2016 - December 2019

​

PhD Researcher Tumor Immunology

University Medical Centre Groningen, the Netherlands

November 2011 -November 2015

​

​

​

​

Publications

Peer-reviewed journal articles

Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer

​

The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers

​

Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome

​

A transcriptionally distinct CXCL13+CD103+CD8+ T-cell population is associated with B-cell recruitment and neoantigen load in human cancer

​

Prognostic significance of tumor-infiltrating B cells and plasma cells in human cancer

​

Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer

​

CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy.

​​

CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma

​

C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity

​

Interleukin-6 receptor and its ligand interleukin-6 are opposite markers for survival and infiltration with mature myeloid cells in ovarian cancer

​

​

​

​

​

​Online Articles and Blogs

wouterswriting.contently.com

​

Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers

Size matters: survival benefit conferred by intratumoral T cells is dependent on surgical outcome, treatment sequence and T cell differentiation

​

Treatment regimen, surgical outcome and T cell differentiation influence prognostic benefit of tumor-infiltrating lymphocytes in high grade serous ovarian cancer

​

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α 2b in patients with recurrent epithelial ovarian cancer

​

CD20+ T cells have a predominantly Tc1 Effector Memory phenotype and are expanded in the ascitis of patients with ovarian cancer

​​

Textbook chapter

Chapter 34: The multifaceted roles of B cells and plasma cells in anti-tumor immunity

​

Conference/meeting reports

The Summit for Cancer Immunotherapy (Summit4CI), June 26–29, 2016 Halifax, Canada

​

8th Annual Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015—May 20–22, Vancouver, Canada

​

​

​

​

​